FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00Cassava up; co expects late-stage trial data for Alzheimer's drug in December
Press Digest: New York Times business news - July 19
Cassava Sciences CEO Remi Barbier steps down (updated)
Biotech firm Cassava Sciences' CEO steps down
Brief: Cassava Sciences Announces Changes in Executive Leadership
U.S. STOCKS ON THE MOVE-Tesla, Apple, AMD, Merck
U.S. STOCKS ON THE MOVE-Masimo, Floor & Decor Holdings, JPMorgan Chase
Brief: Cassava Sciences Says Engaging With DOJ And SEC Regarding Ongoing Investigations Into Co & Two Senior Employees
Cassava Sciences forms panel after probes by U.S. regulators; shares drop
Cassava Sciences forms internal panel after U.S. regulatory probe into two employees (updated)
Cassava Sciences forms internal committee after probes by U.S. regulators into two employees
US professor charged with manipulating data for Alzheimer’s drug trial (updated)
Cassava Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cassava Sciences Q1 Basic EPS USD 0.58
Cassava Sciences Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cassava Sciences Q4 Basic EPS USD -0.5
Cassava Sciences Inc expected to post a loss of 52 cents a share - Earnings Preview